Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
Interventions: DRUG: Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant|DRUG: Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy
Sponsor: Novartis Pharmaceuticals